Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Atomo Diagnostics Ltd. ( (AU:AT1) ) has issued an update.
Atomo Diagnostics Limited announced that it will release its Q3 FY25 results on April 24, 2025, with a briefing webinar scheduled for April 30, 2025. This announcement is part of Atomo’s ongoing efforts to engage with analysts and investors, reflecting its commitment to transparency and stakeholder communication. The release of these results and the subsequent webinar could provide insights into the company’s financial health and strategic direction, potentially impacting its market positioning and stakeholder confidence.
More about Atomo Diagnostics Ltd.
Atomo Diagnostics Limited is an Australian-headquartered medical device company that provides unique, integrated rapid diagnostic test devices to the global diagnostic market. The company’s patented devices enhance usability and reliability for rapid point-of-care and at-home testing applications. Atomo has commercialized products internationally and has supply agreements for testing applications targeting infectious diseases such as COVID-19, HIV, viral vs bacterial differentiation, and female health.
Average Trading Volume: 442,443
Technical Sentiment Signal: Buy
Current Market Cap: A$12.78M
Find detailed analytics on AT1 stock on TipRanks’ Stock Analysis page.